The 1100 study is looking at a new treatment for people with advanced cancers. This study is testing a special kind of medicine called NBTXR3, which is injected directly into a tumor and then activated by radiotherapy (a type of treatment that uses high-energy rays to kill cancer cells). After this, patients will also get a type of medicine called anti-PD-1 therapy, which helps the immune system fight cancer cells.

The study is divided into two parts: dose escalation (testing different doses) and expansion (giving the treatment to more people to gather more information). It includes patients who have certain types of cancer that have spread to areas like the lungs or liver.

Participants will receive one injection of NBTXR3, followed by radiotherapy, and then anti-PD-1 therapy. After completing the treatment, there will be a final visit four weeks later, and patients will be followed for two years to monitor their safety and how well the treatment works.

• The study lasts for about two years with regular follow-ups.
• Participants will receive a single injection and radiotherapy.
• There may be risks, so discussing with a doctor is important.